Multiple Sclerosis Treatment With Autologous Hematopoietic Stem Cell Transplantation in the Netherlands

The proportion of patients with ne evidence of disease activity-3 (NEDA-3) as defined by: no clinical relapse, no disability progression, no radiological disease activity.

Measured by the Expanded Disability Status Scale (EDSS) CDP-EDSS is defined as an increase of one point in the EDSS score from baseline to month 24.

Measured by the Expanded Disability Status Scale (EDSS) CDI-EDSS is defined as a decrease of one point in the EDSS score from baseline to month 24, with an absence of relapse at the point of assessment.

Defined as an episode of CDP without relapse during the 90 days before EDSS increase and during the 6-month period between the EDSS increase and the confirmation of disability progression.

MSFC consists of the timed 25-foot walk test, 9-hole peg test and standard digit modalities test (SDMT)

Presence and number of contrast-enhancing lesions at baseline and the development of new or enlarging lesions between baseline and follow-up will be assessed.

Developments of optic neuritis and longitudinal changes of the retinal nerve fiber layer will be assessed.

Frequency and type of (serious) adverse events such as infections, secondary auto-immunity, fertility problems, clinical relevant changes on physical examination and use of concomitant medications will be assessed

Patient reported outcome measures about the impact of MS on daily life

Patient reported outcome measures about quality of life

Patient reported outcome measures about fatigue

Patient reported outcome measures about anxiety and depression

Patient reported outcome measures about medical consumption

Patient reported outcome measures about productivity

Patient reported outcome measures about medication

Serum NfL and GFAP over time

Olink discover panel

Characterization of innate and adaptive immune subsets with mass spectrometry imaging

Immune gene profiling for gene signatures predictive for response to aHSCT